Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT03038308 : Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole
PhasePhase 1/Phase 2
AgesMin: 18 Years Max: 70 Years
Inclusion Criteria:

- Ages 18-70 years

- Prolactin level (PRL) ?2 times upper limit of normal

- Pituitary adenomas on MRI ? 1.5cm in greatest diameter and ? 5mm from the optic

- Normal renal and liver function

- Agrees to barrier contraception if pre-menopausal

Exclusion Criteria:

- Use of medications known to interfere with PRL secretion and PRL and Ropinirole (ROP)

- Use of another dopamine agonist during the 4 weeks prior

- Pituitary stalk compression on MRI

- History of visual field abnormalities or previous radiation

- Untreated hypothyroidism

- Consumption of > 2 alcoholic drinks per day

- Pregnancy
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557